P
ProHub
English 简体中文 繁體中文
Medium PE / Private Equity Merger & Acquisition Profitability

OncoCo

#Healthcare
ProHub Comment

This is a comprehensive M&A case requiring candidates to diagnose why OncoCo's profits are declining (patent expiration leading to generic competition) and evaluate whether acquiring liquid morphine rights is strategically and financially sound. The case tests both quantitative analysis (margin calculations, market share requirements) and qualitative reasoning (business model fit, reputational risks, operational capability).

Estimated Time 27 minutes
Difficulty Medium
Source IESE
10 / 100

A private equity client owns a specialized pharma manufacturer called OncoCo which focuses on cancer treatments. OncoCo is not only profitable, but also experienced steady growth in the past years. Hence, the PE fund was surprised when the management board of OncoCo stated that they expect declining profits in the future. OncoCo’s management board has also suggested, to cushion the decline with the acquisition of an additional asset. In particular, OncoCo’s board received the opportunity to purchase the commercial rights of liquid morphine.

The PE fund has asked us to figure out why a decline is expected and whether they should move forward with the acquisition.

Clarifying Information

  1. PE target: EBITDA margin > 20%
  2. Liquid Morphine: Used to treat severe pain, for example after an operation or a serious injury, or pain from cancer or a heart attack. Morphine liquid is fast acting and used for pain which is expected to last for a short time, e.g. when you start taking other forms of morphine to help find the right dose. Usually morphine is prescribed by pain specialists
  3. Commercial rights means that OncoCo will be able to produce and sell the product under its name. Often pharma companies purchase existing stocks and have the opportunity to either renegotiate the contracts with raw material suppliers or continue under existing conditions
  4. Declining revenue: expect a drop in revenues of 100m€
  5. BM: OncoCo’s income stems from one drug to treat a very niche, late stage cancer
  6. Price (treatment costs) per year: 10k€
  7. Location: EU
Mock Interview
Interviewer

A private equity client owns a specialized pharma manufacturer called OncoCo which focuses on cancer treatments. OncoCo is not only profitable, but also experienced steady growth in the past years. Hence, the PE fund was surprised when the management board of OncoCo stated that they expect declining profits in the future. OncoCo's management board has also suggested, to cushion the decline with the acquisition of an additional asset. In particular, OncoCo's board received the opportunity to purchase the commercial rights of liquid morphine. The PE fund has asked us to figure out why a decline is expected and whether they should move forward with the acquisition.

You

Thanks. Before analyzing, I'd like to clarify a few key questions...

Interviewer

Good question. Let me provide some background information...

You

Based on this, I suggest analyzing from these dimensions...

AI Score
Structure Analysis Communication Business Sense Quantitative
Practicing...
Score coming soon
Practice this case with AI Mock Interview

A PE-backed cancer drug specialist faces declining profits due to patent expiration of its core product. Management proposes acquiring commercial rights to liquid morphine to offset the decline. Candidates must analyze OncoCo’s current business deterioration, assess the morphine market opportunity, and determine whether the acquisition makes strategic and financial sense despite attractive margins.

Key Insights:

  1. Patent expiration is the root cause of OncoCo’s revenue decline (2/3 drop expected) due to generic competition entry
  2. The target asset (liquid morphine) has attractive 32% EBITDA margin meeting PE’s >20% target, but generates lower absolute profit ($25m vs current $40m)
  3. Critical mismatch: OncoCo operates a specialized niche business model while morphine is a mass-market product requiring different capabilities (production, sales, regulatory)
  4. Opioid crisis reputation risk could damage OncoCo’s brand and enterprise value long-term despite financial metrics
  5. To achieve same profit as current product, OncoCo would need 40% market share (vs current 25%) requiring major market consolidation
  6. Recommendation hinges on qualitative factors (business model fit, operational capability, reputational risk) not just quantitative margin analysis